Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering (NASDAQ:IMRX) announced plans to release updated overall survival data from its Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025. The trial data, with 9 months median follow-up, follows previously reported exceptional 94% overall survival at 6 months, significantly outperforming the standard of care's 67% survival rate.
The company will present the data through an investor call and webcast, followed by a presentation at the PanCAN Scientific Summit on September 28. Additionally, Immuneering will present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has successfully closed a $25 million private placement with institutional and accredited investors. The transaction included the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, along with warrants to purchase 2,848,096 additional shares at $5.50 per share.
The offering also included pre-funded warrants at $3.949 per share. The purchase warrants have a five-year exercise period following registration. Leerink Partners served as financial advisor for the placement, which was conducted as a private transaction under Securities Act regulations.
Immuneering (Nasdaq: IMRX) has entered into a clinical supply agreement with Eli Lilly to evaluate its lead product candidate atebimetinib in combination with Lilly's olomorasib in a planned Phase 2 trial. The study will focus on patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.
This marks Immuneering's second major collaboration in 2025, following a February agreement with Regeneron to evaluate atebimetinib with Libtayo®. Preclinical studies of the atebimetinib-olomorasib combination have shown promising results, including enhanced tumor regression and delayed resistance. Immuneering will retain global development and commercialization rights to atebimetinib.
Immuneering (Nasdaq: IMRX) has secured a $25 million private placement from institutional and accredited investors. The company is offering 6,329,113 shares at $3.95 per share, a 15% premium to the previous closing price, along with warrants to purchase 2,848,096 additional shares at $5.50 per share.
The financing was driven by strong investor interest following impressive clinical results, including a 94% overall survival rate at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP, significantly outperforming the standard of care's 67% survival rate. The funding will support the development of Deep Cyclic Inhibitors, including atebimetinib, a MEK inhibitor targeting the MAPK pathway.
Immuneering (NASDAQ:IMRX) reported Q2 2025 financial results and significant clinical progress for its lead drug atebimetinib. The company highlighted exceptional 94% overall survival at 6 months in first-line pancreatic cancer patients (N=34) treated with atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP), compared to 67% with standard care.
Key developments include a newly granted U.S. composition of matter patent extending exclusivity into 2042, and a notable case of a third-line pancreatic cancer patient maintaining partial response for over 18 months on atebimetinib monotherapy. The company reported Q2 2025 net loss of $14.4 million ($0.40 per share) and cash position of $26.4 million, with runway into 2026.
Immuneering plans to share updated survival data in Q3 2025 and has submitted an End of Phase 2 meeting request to FDA, with pivotal trial initiation expected in 2026.
Immuneering (Nasdaq: IMRX) has secured a crucial U.S. composition of matter patent for atebimetinib, its innovative cancer drug candidate. The patent, expected to provide exclusivity until August 2042, covers this first-in-class deep cyclic MEK inhibitor designed as a once-daily pill to combat cancer drug resistance.
Clinical data has shown remarkable results, with 94% probability of 6-month survival in first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, compared to 67% with standard care. The drug has received FDA Fast Track designations for first- and second-line pancreatic cancer treatment and NRAS-mutant melanoma, along with orphan drug designation for pancreatic cancer.
Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place at the Marriott Marquis in New York City from June 4-5, 2025.
The company's management team, including CEO Ben Zeskind, CMO Igor Matushansky, CSO Brett Hall, CBO Harold Brakewood, and CAO Mallory Morales, will deliver a company presentation on June 5 from 8:45-9:15 am ET. The presentation will focus on Immuneering's pipeline, platform, and business strategy. The event will also include one-on-one investor meetings.
A live webcast of the presentation will be available and later archived in the Investor Relations section of Immuneering's website.